Abstract
Cervical cancer is a significant public health problem in developing countries, as most cases present at an advanced stage. This review aimed to analyze the role of non-coding RNAs as diagnostic and prognostic biomarkers in cervical cancers. Published studies on specific microRNA signatures in body fluids and cervical cancer tissues are highly heterogeneous, and there are no validated assays. The precision of the various immune-associated lncRNA signatures should be assessed in clinical samples. Even though lncRNAs are tissue and cancer-specific, safe and appropriate methods for delivery to tumor tissues, toxicities and side effects are to be explored. Few studies have evaluated deregulated lncRNA expression levels with clinicopathological factors in a limited number of clinical samples. Prospective studies assessing the diagnostic and prognostic roles of circulating lncRNAs and P-Element-induced wimpy testis interacting PIWI RNAs (Piwil RNAs) in cervical ca ncer cases are essential. For the clinical application of lnc-RNA-based biomarkers, comprehensive research is needed as the impact of non-coding transcripts on molecular pathways is complex. The standardization and validation of deregulated ncRNAs in non-invasive samples of cervical cancer cases are needed.
This article is protected by copyright. All rights reserved.
No comments:
Post a Comment